THURSDAY, 8TH DECEMBER 2016

8:00 - 20:00  Arrivals, registration
9:30 - 10:00  Break (foyer Lobby)
10:00 - 11:30 Meeting of Biology Treatment Centres of the Czech Republic (Nadir)
11:30 - 12:30 Lunch for participants of Meeting of Biology Treatment Centres (foyer Lobby)

HALL ZENIT
12:30 - 13:40 Opening Session
   Chair: Vencovský J, Pavelka K.
   12:30 - 13:00  0:30 Opening
   13:00 - 13:20  0:20 O 1. Epigenetics Regulating our Cells and Mind in Health and Disease.
                   Gay S (Department of Rheumatology, University Hospital Zurich, Switzerland)
                   Gay R (Department of Rheumatology, University Hospital Zurich, Switzerland)
13:40 - 13:45  0:05 Break - foyer Lobby

HALL ZENIT
13:45 - 15:15 General Session 1: Systemic Sclerosis
   Chair: Distler O, Tomčík M.
                   Distler O (Department of Rheumatology, University Hospital Zurich, Switzerland)
   14:05 - 14:25  0:20 O 4. Efficacy of an Intensive 24-week Physiotherapy Programme in Sclero-
                   derma Patients - Preliminary Data from a Single-center Controlled Study.
                   Tomčík M (Institute of Rheumatology, Dept. of Rheumatology, 1st Faculty of Medicine, Charles
                   University, Prague, Czech Republic)
                   Bečvář R (Institute of Rheumatology, Prague, Czech Republic)
   14:45 - 14:55  0:10 O 6. Eradication of Helicobacter Pylori Reduces Disease Severity and Activity
                   in Systemic Sclerosis Patients
                   Radič M (Division of Rheumatology and Clinical Immunology, Center of excellence for Systemic
                   Sclerosis in Croatia, University Hospital Center Split, Croatia)
                   Study of 11 Systemic Sclerosis Patients
                   Běly M (Department of Pathology, Hospital of the Order of the Brothers of Saint John of God in
                   Budapest, Hungary)
   15:05 - 15:15  0:10 O 8. Psychological Profile Detected by MMPI-IIand BDI-II Tests by Patient with
                   Scleroderma
                   Smržová A (3rd Department of Internal Medicine - Nephrology, Rheumatology And Endocrinology,
                   Faculty Hospital and University Palacky Olomouc, Czech Republic)
15:15 - 15:45  0:30 Break – foyer Lobby
### HALL ZENIT

**15:45 - 17:15** General Session 2: Cardiovascular Manifestations of Rheumatic Diseases  
Chair: Anic B, Morović-Vergles J

- **15:45 - 16:05**  
  0:20 O 9. Impact of Treatment with Biological Disease Modifying Anti-inflammatory Drugs on Atherosclerosis in Rheumatoid Arthritis Patients.  
  Holc I, Pahor A (University Clinical Center Maribor, Maribor, Slovenia)

- **16:05 - 16:25**  
  0:20 O 10. Association between Anti-cyclic Citrullinated Peptide Antibodies and Myocardial Involvement in Patients with Active Rheumatoid Arthritis.  
  Marasović-Krstulović D, Martinović-Kalitema D (University Hospital Center Split, Split, Croatia)

- **16:25 - 16:45**  
  0:20 O 11. Differences in the Prevalence of Arterial Hypertension and Metabolic Syndrome in Patients with Rheumatoid Arthritis and Patients with Osteoarthritis: The Results of our Study.  
  Salamon L, Morović-Vergles J (University Hospital Dubrava, Zagreb, Croatia)

- **16:45 - 16:55**  
  0:10 O 12. Ambulatory Arterial Stiffness Index and Carotid Intima-media Thickness in Hypertensive Rheumatoid Patients: Experience in our Center.  
  Mitrovic J (Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Dubrava University Hospital, University of Zagreb School of Medicine, Zagreb, Croatia)

- **16:55 - 17:05**  
  0:10 O 13. Comparison of Clinical Characteristics of Diabetes Mellitus Patients with and without Sclerodema Buschke Skin Disorder.  
  Varju C (University of Pecs, Pecs, Hungary)

- **17:05 - 17:15**  
  Schubertová M (Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc, University Hospital Olomouc, Olomouc, Czech Republic)

**17:15 - 17:45** Break - foyer Lobby

### HALL ZENIT

**17:45 - 18:45** Satellite Symposium 1 - Immunology Update 2016 (MSD)  
Chair: Smolen J, Vencovský J

- **17:45 - 18:00**  
  0:15 The Difficult Choice - Comparing the Efficacy of Different Biological DMARDs.  
  Smolen J, Vienna, Austria

- **18:00 - 18:15**  
  0:15 Use of Antirheumatic Drugs During Pregnancy and Lactation.  
  Vencovský J, Prague, Czech Republic

- **18:15 - 18:30**  
  0:15 Uveitis in Rheumatic Disorders and its Therapeutic Possibilities.  
  Heissigerová J, Prague, Czech Republic

- **18:30 - 18:45**  
  0:15 Impact of AS on Work Disability and Influence of Anti TNF Therapy.  
  Pavelka K, Prague, Czech Republic

### HALL NADIR

**17:45 - 18:45** Satellite Symposium 2 - Right Treatment for the Right Patient - Making Successful Therapeutic Decisions Based on Different Patient Profiles (UCB)  
Chair: Kucharz EJ, Szekecz Z.

- **17:45 - 18:00**  
  0:15 News in the Diagnosis and Treatment of axSpA and nr-axSpA Patients.  
  Pavelka K, Prague, Czech Republic

- **18:00 - 18:15**  
  0:15 Role of MRI in Early Diagnostic of nr-AxSpA Patients.  
  Žínay M, Piešťany, Slovakia

- **18:15 - 18:30**  
  0:15 Early Diagnosis and Guideliness in Rheumatoid Arthritis.  
  Kucharz EJ, Katowicz, Poland
## SCIENTIFIC PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 18:30 - 18:45 | Differences between Anti-TNFs - what do the H2H Studies Tell us?  
Psenak O, Salzburg, Austria |

**CONGRESS FOYER, TYCHO, KEPLER**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:15 - 22:15</td>
<td>Networking</td>
</tr>
</tbody>
</table>

## FRIDAY, 9TH DECEMBER 2016

### HALL ZENIT

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:30 - 10:00 | General Session 3: Environmental Factors  
Chair: Szekanecz Z, Czirjak L |
| 8:30 - 8:42 | O 15. Influence of Environmental Factors on Comorbidities of Generalized Osteoarthritis.  
Kvádr E, Bálint PV (National Institute of Rheumatology and Physiotherapy, Budapest, Hungary) |
Czirjak L (University of Pécs, Department of Rheumatology and Immunology, Pécs, Hungary) |
| 8:54 - 9:06 | O 17. Immune Mediated Necrotising Myopathy Associated with Statins.  
Vencovsky J (Institute of Rheumatology, Prague, Czech Republic) |
Pálinkás M, Pódr G (National Institute of Rheumatology and Physiotherapy, Budapest, Hungary) |
Szekanecz Z (University of Debrecen, Hungary) |
Nagy G (Semmelweis University, Department of Rheumatology, Hungary) |
Kovács I. et al (University of Szeged, Faculty of Medicine, Department of Rheumatology and Immunology, Hungary) |
| 9:50 - 10:00 | O 22. Analysis of ABCG2, SLC17A3, SLC22A11and SLC17A1 Genes in Patients with Primary Hyperuricemia and Gout.  
Petrů L (Institute of Rheumatology, Prague, Czech Republic) |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:30</td>
<td>Break - foyer Lobby</td>
</tr>
</tbody>
</table>

### HALL ZENIT

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:30 - 11:30 | Satellite Symposium 3 - Decoding the Complex Interplay in PsA (Celgene)  
Chair: Štolfa J, Thaci D |
| 10:30 - 10:50 | Etiopathogenesis of PsA.  
Thaci D, Lübeck, Germany |
| 10:50 - 11:10 | Apremilast - a New Oral Therapy in PsA.  
Pavelka K, Prague, Czech Republic |
| 11:10 - 11:30 | Apremilast in European and GRAPPA Recommendations.  
Štolfa J, Sedová L, Prague, Czech Republic |

### HALL NADIR

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:30 - 11:30 | Satellite Symposium 4 - Treat to Target in SpA. (Novartis)  
Chair: Smolen J, Vencovsky J |
| 10:30 - 10:45 | TZT in SpA.  
Smolen J, Vienna, Austria |
SCIENTIFIC PROGRAMME

10:45 - 11:00  0:15  Role of IL-17 in Pathophysiology of SpA.  
Vencovský J, Prague, Czech Republic

11:00 - 11:15  0:15  IL-17 Inhibitors (Cos) in the Context of the New EULAR PsA Guidelines.  
Praprotník S, Slovenia

11:15 - 11:30  0:15  IL-17 Inhibitors (Cos) in the Context of the New EULAR AS Guidelines.  
Mann H, Prague, Czech Republic

11:30 - 11:35  0:05  Technical break

HALL ZENIT

11:35 - 13:05  General Session 4: Psoriatic Arthritis, Vasculitis  
Chair: Rovenský J, Tesař V

11:35 - 11:55  0:20  O 23. Disease Activity Assessment in Psoriatic Arthritis - Definition of Remission and other Outcomes.  
Smolen J (Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Austria)

Rovensky J, Kozák I (National Institute of Rheumatic Diseases, Piešťany, Slovakia)

Tesař V (Department of Nephrology, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic)

Lukáč J (Institute of Physiotherapy, Balneology and Medical Rehabilitation and National Institute of Rheumatic Diseases, Piešťany, Slovakia)

Bradna P (2nd Department of Internal Medicine, 3rd Department of Internal Medicine, Dept. of Immunology, Charles University Faculty of Med, University hospital, Hradec Kralove, Czech Republic)

Szántó S (Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)

FOYER LOBBY, VIRGO

13:05 - 14:05  1:00  Boxed Lunch and Poster Session and Selected Poster Tour

HALL ZENIT

14:05 - 15:35  General Session 5: Malignancy and Rheumatic Diseases. Epidemiology  
Chair: Kucharz E, Wiland P.

14:05 - 14:25  0:20  O 29. Rheumatic Diseases and Malignancy: from Bench to Bedside.  
Kucharz EJ (Department of Internal Medicine and Rheumatology, Medical University of Silesia, Katowice, Poland)

14:25 - 14:45  0:20  O 30. Paraneoplastic Syndromes in Rheumatology.  
Kotyla P (Department of Internal Medicine and Rheumatology, Medical University of Silesia, Katowice, Poland)

Bakko B (Department of Rheumatology, J. Dietl Specialist Hospital, Krakow, Poland) presenting author - Wiland P
## Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:05 - 15:15</td>
<td>O 32. The Efficacy of Stopping Biologicals in Patients with SpA. Tłustochowicz M (Department of Internal Diseases and Rheumatology, Military Institute of Medicine, Warsaw, Poland) presenting author – Raczkiewicz A</td>
</tr>
<tr>
<td>15:15 - 15:25</td>
<td>O 33. Neoplasma in Rheumatoid Arthritis patients - our Experience Guđelj Gračanin A (Division of Clinical Immunology, Allergology and Rheumatology, Department of Internal Medicine, Croatia)</td>
</tr>
<tr>
<td>15:25 - 15:35</td>
<td>O 34. Accumulation of S100A11 Protein in Rheumatoid Arthritis and its Correlation with Disease Activity and Inflammation. Andrés Cerezo L (Institute of Rheumatology, Prague, Czech Republic)</td>
</tr>
<tr>
<td>15:35 - 16:05</td>
<td>Break - foyer Lobby</td>
</tr>
</tbody>
</table>

### Hall Zenit

**16:05 - 17:05** Satellite Symposium 5 - A different Journey is Possible for Patients with Spondyloarthritis (AbbVie)  
Chair: Bálint P, Šenolt L

- **16:20 - 16:35** Role of Imaging in Progression Evaluation in Patients with Axial Spondyloarthritis. Grobelná K, Prague, Czech Republic
- **16:35 - 16:50** Long-term Safety and Efficacy of Adalimumab for the Treatment of Ankylosing Spondylitis - Data from ATTRA Registry. Šenolt L, Prague, Czech Republic
- **16:50 - 17:05** Translating PsA Guidelines into Practice: National Guidelines Update. Štolfa J, Prague, Czech Republic

### Hall Nadir

**16:05 - 17:05** Satellite Symposium 6 (Biogen)  
Chair: Vencovský J, Kucharz EJ

- **16:05 - 16:20** Comorbidities in Patients with Rheumatoid Arthritis. Kucharz EJ, Katowicz, Poland
- **16:25 - 16:45** Current Situation of Biosimilars in Rheumatology. Vencovský J, Prague, Czech Republic
- **16:45 - 17:05** EULAR Recommendations and their Impact on Clinical Practice in Central Europe. Pavelka K, Prague, Czech Republic

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:05 - 17:10</td>
<td>Technical break</td>
</tr>
</tbody>
</table>

### Hall Zenit

**17:10 - 18:55** General Session 6: Young Rheumatologists from CECR Countries  
Chair: Šenolt L, Nagy

- **17:10-17:25** O 35. Neutrophil CARD9 Mediates Autoantibody-induced Autoimmune Diseases by Controlling Gene Expression Changes in vivo. Németh T (Department of Physiology, Semmelweis University School of Medicine, Budapest, Hungary)
- **17:25-17:40** O 36. Increased Interest in Polymyalgia Rheumatic and Giant Cell Arteritis Leads to Increased Incidence. Milchert M (Pomeranian Medical University, Klinika Reumatologii, Szczecin, Poland)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:40</td>
<td><strong>O 37. Antiprothrombin Antibodies in the Diagnosis of APS.</strong> Zheng P (University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia)</td>
</tr>
<tr>
<td>17:40</td>
<td><strong>O 38. Cytokine Responses of T Cells, B Cells and Monocytes in Patients with Rheumatoid Arthritis: Effects of IL-35.</strong> Mravcová M (Institute of Experimental Endocrinology, Biomedical Research Centre, Slovak Academy of Sciences, Bratislava, Slovakia)</td>
</tr>
<tr>
<td>18:10</td>
<td><strong>O 39. The Role of Immunosenescence in Rheumatic Diseases.</strong> Fessler J (Medizinische Universität, Klinische Abteilung für Rheumatologie und Immunologie, Graz, Austria)</td>
</tr>
<tr>
<td>18:25</td>
<td><strong>O 40. Cardiovascular Damage in Deceased Patients with Systemic Lupus Erythematosus.</strong> Padjen I (University Hospital Centre Zagreb and University of Zagreb, School of Medicine, Croatia)</td>
</tr>
<tr>
<td>18:40</td>
<td><strong>O 41. IL-35 in the Pathogenesis of Rheumatic Diseases.</strong> Filková M (Institute of Rheumatology, Department of Rheumatology of the 1st Faculty of Medicine, Charles University, Czech Republic)</td>
</tr>
</tbody>
</table>

19:00 Departure of Busses for Networking Event from the Hotel Clarion Reception

**VILLA RICHTER - PRAGUE CASTLE**

19:45 - 22:45 Networking Event

---

**SATURDAY, 10TH DECEMBER 2016**

**HALL ZENIT**

8:30 - 10:00 General Session 7: Antiphospholipid Syndrome
Chair: Holc I, Ambrožič A

8:30 - 8:50 **O 42. Antiphospholipid Syndrome: Clinical Manifestations and Treatment.** Ambrožič A (Clinical Dept. of Rheumatology, UMC Ljubljana, Slovenia)

8:50 - 9:10 **O 43. Venous Thrombosis and Antiphospholipid Antibodies.** Perdan Pirkmajer A, Ambrožič A (Clinical Dept. of Rheumatology, UMC Ljubljana, Slovenia)

9:10 - 9:30 **O 44. Antiphospholipid Antibodies, a Possible Etiologic Factor for Cerebrovascular Events in Younger Adult Patients.** Gašperšič N (Clinical Dept. of Rheumatology, UMC Ljubljana, Slovenia)

9:30 - 9:45 **O 45. Antiphospholipid Antibodies in Association to Adverse Pregnancy Outcome.** Žigon P (Clinical Dept. of Rheumatology, UMC Ljubljana, Slovenia)

9:45 - 10:00 **O 46. Pregnancy in Antiphospholipid Syndrome.** Kovačič Grobelšek V, Holc I (Dept. of Rheumatology, Division of Internal Medicine, UMC Maribor, Slovenia)

---

**FOYER LOBBY, VIRGO**

10:00 - 11:00 1:00 Break and Poster Session and Selected Poster Tour

---

**HALL ZENIT**

11:00 - 12:20 General Session 8: Easy and Early Access Rheumatology
Chair: Machold K, Nell V

11:00 - 11:20 **O 47. Providing Timely Access to Rheumatology Services: Review of the International Approaches.** Nell V (Klinikum Peterhof Baden, Austria)
<table>
<thead>
<tr>
<th>Time</th>
<th>Duration</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:20 - 11:40</td>
<td>0:20</td>
<td><strong>O 48. The Austrian Central University Hospital Approach.</strong></td>
<td>Machold K (Medical University of Vienna, Austria)</td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>0:20</td>
<td><strong>O 49. The Austrian Office Based Cooperative Approach.</strong></td>
<td>Puchner R (Rheumatology Practice Wels, Austria)</td>
</tr>
<tr>
<td>12:00 - 12:10</td>
<td>0:10</td>
<td><strong>O 50. Patients’ Dogma, Number of Swollen Joints and Physicians’ and Patients’ Age Predict Non-adherence to Medicines and Non-pharmacological Interventions in Rheumatoid Arthritis - a Mixed Methods Study</strong></td>
<td>Ritschl V (Institute of Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Austria)</td>
</tr>
<tr>
<td>12:10-12:20</td>
<td>0:10</td>
<td><strong>O 51. Effectiveness of a Workplace-centered Initiative to Consuel Individuals with Musculoskeletal Complaints (WORIMUCO): A prospective Pilot Cohort Study.</strong></td>
<td>Leiss H (MUV, Department of Rheumatology, Austria)</td>
</tr>
<tr>
<td>12:20 - 12:35</td>
<td>0:15</td>
<td><strong>Summary and Close</strong></td>
<td></td>
</tr>
</tbody>
</table>